Understanding the Impact of Sex, Treatment Resistance, and Antidepressant Treatment on Monoamine Oxidase B

What is the Relationship Between MAO-B and Mental Health?

Research has shown that elevated levels of monoamine oxidase B (MAO-B) are implicated in the pathophysiology of several common neuropsychiatric diseases, including Alzheimer's disease, traumatic brain injury, and major depressive disorder. A recent study published on medRxiv aimed to examine the effect of treatment-resistant major depressive episodes, sex, and antidepressant treatment on MAO-B total distribution volume ([11C]SL25.1188 VT), an index of MAO-B level.

How Does MAO-B Affect the Brain?

MAO-B is a high-density protein located mainly in astrocytes that influences mitochondrial function and transition to astrogliosis. While metabolizing non-serotonergic monoamines, MAO-B produces hydrogen peroxide, which can have detrimental effects on brain health. Understanding the relationship between MAO-B and mental health is essential for developing effective treatments for neuropsychiatric diseases.

What Did the Study Find?

The study involved 95 adults, including 29 with major depressive episodes (MDE) and no history of treatment-resistance (NTR-MDE), 26 with MDE and history of treatment-resistance (TRD), and 40 healthy controls (HC). A subset of NTR-MDE and TRD participants (n=13) were scanned before and after treatment with phenelzine, rasagiline, or duloxetine. The results showed that [11C]SL25.1188 VT was higher in grey matter regions in females (10%, p<.001). Additionally, [11C]SL25.1188 VT was also higher in the prefrontal cortex in TRD compared to HC (23%, p<.001) and TRD compared to NTR-MDE (6%, p=.033).

What is the Significance of Sex Differences in MAO-B Level?

The study discovered sex differences in MAO-B level, which may explain sex differences in prevalence or trajectory of illnesses with greater MAO-B level. This finding has significant implications for the development of treatments that target MAO-B, particularly for women who may be more susceptible to these diseases.

How Do Different Antidepressants Affect MAO-B Level?

The study found that duloxetine had minimal effect on [11C]SL25.1188 VT, but occupancy of rasagiline and phenelzine was ~94%. This suggests that MAO-B inhibitors, such as rasagiline and phenelzine, may be effective in reducing MAO-B level in individuals with treatment-resistant depression.

What are the Implications of This Study?

Given the findings of greater MAO-B level in the prefrontal cortex of TRD and its insensitivity to serotonin reuptake inhibition, combined with potential harm of highly elevated MAO-B level, development of MAO-B inhibitors could be considered for a subset of TRD. Additionally, the study highlights the importance of considering sex differences in the development of treatments for neuropsychiatric diseases.

What are the Next Steps?

Future studies should aim to replicate these findings and explore the potential benefits of MAO-B inhibitors in individuals with treatment-resistant depression. Additionally, further research is needed to understand the mechanisms underlying sex differences in MAO-B level and their implications for disease development and treatment.

What are the Key Takeaways?

• Elevated levels of MAO-B are implicated in the pathophysiology of several common neuropsychiatric diseases.
• Sex differences in MAO-B level may explain sex differences in prevalence or trajectory of illnesses with greater MAO-B level.
• MAO-B inhibitors, such as rasagiline and phenelzine, may be effective in reducing MAO-B level in individuals with treatment-resistant depression.
• Development of MAO-B inhibitors could be considered for a subset of TRD.
• Further research is needed to understand the mechanisms underlying sex differences in MAO-B level and their implications for disease development and treatment.

What are the Related Queries?

• What are the implications of elevated MAO-B level for neuropsychiatric disease development and treatment?
• How do sex differences in MAO-B level impact disease prevalence and trajectory?
• What are the potential benefits of MAO-B inhibitors in individuals with treatment-resistant depression?
• How can we develop effective treatments that target MAO-B, particularly for women who may be more susceptible to these diseases?

What are the Expert Comments?

This study provides valuable insights into the relationship between MAO-B and mental health, highlighting the importance of considering sex differences in the development of treatments for neuropsychiatric diseases. The findings suggest that MAO-B inhibitors may be effective in reducing MAO-B level in individuals with treatment-resistant depression, and further research is needed to explore this potential therapeutic avenue.

What are the FAQs?